Healthy volunteers help compare new biosimilar to taltz
NCT ID NCT07200986
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests whether a new biosimilar medicine (CT-P52) works similarly to the approved drug Taltz in the body. It involves 218 healthy adults aged 19 to 55 who receive a single dose of either the biosimilar or Taltz. The main goal is to compare how the drug is absorbed and its safety, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
-
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
-
Inje University Busan Paik Hospital
Busan, Busanjin-gu, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
-
Seoul National University Hospital
Seoul, South Korea